8-K: Amicus Therapeutics Achieves Q3 Profitability, Strong Revenue Growth

Amicus Therapeutics reported strong third-quarter 2025 financial results, achieving GAAP net income of $17 million on total revenues of $169 million, up 17% at constant exchange rates.

Summary

• Total revenues for the third quarter 2025 were $169.1 million, reflecting strong operational growth of 17% at constant exchange rates (CER) and a currency tailwind of ~$4 million.
• Achieved GAAP net income of $17.3 million, or $0.06 per share basic and diluted, for the third quarter 2025, compared to a GAAP net loss of $6.7 million in Q3 2024.
• Non-GAAP net income was $54.2 million, or $0.18 per share basic and $0.17 diluted, for Q3 2025, up from $30.8 million in Q3 2024.
• Cash, cash equivalents, and marketable securities increased to $263.8 million at September 30, 2025, from $249.9 million at December 31, 2024.
• Galafold net product sales for Q3 2025 were $138.3 million, a year-over-year increase of 15%, or 12% at CER.
• Pombiliti + Opfolda net product sales for Q3 2025 were $30.7 million, a year-over-year increase of 45%, or 42% at CER.
• Total GAAP operating expenses for Q3 2025 increased by 8% to $115.3 million compared to $106.6 million for Q3 2024.
• Enrollment in the Phase 3 ACTION3 study of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) remains on track for completion by year-end 2025.
• Reiterated 2025 financial guidance: Total Revenue Growth 15% to 22% (CER), Galafold Revenue Growth 10% to 15% (CER), Pombiliti + Opfolda Revenue Growth 50% to 65% (CER), Gross Margin Mid 80%, Non-GAAP Operating Expenses $380M to $400M, and positive GAAP Net Income during H2 2025.
• The company anticipates surpassing $1 billion in total sales in 2028.

Sentiment

Score: 8

Explanation: The company reported strong financial results, achieving GAAP profitability, significant revenue growth across its key products, and maintained positive full-year guidance. Progress in clinical trials and market expansion for new therapies further enhances the positive outlook, indicating robust operational execution and strategic advancement.

Positives

• Achieved GAAP net income of $17.3 million in Q3 2025, a significant turnaround from a GAAP net loss of $6.7 million in Q3 2024.
• Total revenues grew 17% at constant exchange rates (CER) to $169.1 million, demonstrating strong operational performance.
• Galafold sales increased 15% (12% at CER) to $138.3 million, driven by continued commercial execution, new patient starts, and strong compliance.
• Pombiliti + Opfolda sales surged 45% (42% at CER) to $30.7 million, fueled by high commercial demand and new launch countries.
• Cash, cash equivalents, and marketable securities increased by $33 million in Q3 2025, reaching $263.8 million.
• Pombiliti + Opfolda secured pricing and reimbursement agreements in four new countries, including Japan and Belgium, and is on track for up to 10 new launch countries in 2025.
• New 4-year data from the PROPEL open-label extension (OLE) study for Pombiliti + Opfolda showed stability or improvement in measures of muscle function, muscle strength, and biomarkers.
• Manufacturing partner, WuXi Biologics, received European Medicines Agency (EMA) approval for its Dundalk, Ireland facility as a commercial manufacturing site for Pombiliti.
• The Phase 3 ACTION3 study of DMX-200 for FSGS, a rare and fatal kidney disease with no approved therapies, is on track for full enrollment by year-end 2025.
• The company reiterated its strong 2025 financial guidance, including expectations for positive GAAP net income during the second half of 2025.
• Amicus anticipates surpassing $1 billion in total sales in 2028 and delivering sustainable double-digit growth in the years ahead.

Negatives

• GAAP net loss for the nine months ended September 30, 2025, was $28.8 million, despite the profitable third quarter.
• Selling, general, and administrative expenses increased by 20% year-over-year for Q3 2025 and 12.5% for the nine months ended September 30, 2025, indicating rising operational costs.

Risks

• Regulatory authorities may not grant or may delay approval for product candidates.
• Required regulatory inspections may be delayed or not be successful, which could delay or prevent product approval.
• The company may not be successful in negotiations with pricing and reimbursement authorities.
• There is a potential that the company may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US, and other geographies.
• The Dimerix license agreement for DMX-200 may not be successful, including expectations regarding the timing and likelihood of success of the Phase 3 clinical trial.
• Uncertainty exists regarding the prospects for FDA approval of DMX-200 for FSGS or other indications.
• The company may not be able to manufacture or supply sufficient commercial products.
• Additional funding may be needed to complete the manufacturing and commercialization of products.
• Actual financial results may differ materially from corporate financial guidance and goals based on market factors and the company's ability to execute its operational and budget plans.

Future Outlook

Amicus Therapeutics reiterates its 2025 financial guidance, anticipating total revenue growth of 15% to 22% at constant exchange rates, with Galafold revenue growth of 10% to 15% and Pombiliti + Opfolda revenue growth of 50% to 65%. The company expects to achieve positive GAAP net income during the second half of 2025 and projects surpassing $1 billion in total sales by 2028, driven by continued commercial expansion and pipeline advancement.

Management Comments

• "Amicus achieved yet another impressive quarter, delivering revenue growth of 17 percent and reaching the milestone of GAAP profitability. We served more patients than ever before, driven by new Galafold starts and growing adoption for Pombiliti + Opfolda." Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics Inc.
• "Alongside this commercial momentum, enrollment in the Phase 3 study of DMX-200 remains on track for completion by year-end. Through our continued execution, Amicus is well positioned to achieve our 2025 strategic objectives and deliver sustainable double-digit growth in the years ahead." Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics Inc.

Industry Context

Amicus Therapeutics operates in the highly specialized and competitive rare disease biotechnology sector. Its focus on Fabry disease (Galafold) and Pompe disease (Pombiliti + Opfolda) positions it in markets with significant unmet needs, where innovative therapies can command premium pricing. The advancement of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no approved therapies, represents a strategic expansion into another high-value rare disease area, potentially offering a first-in-class treatment. The company's ability to achieve GAAP profitability and strong revenue growth in this niche market demonstrates effective commercialization and pipeline management, distinguishing it within the broader biotech landscape.

Comparison to Industry Standards

• Galafold, as the only approved oral treatment for amenable Fabry disease patients, holds a unique position, with ~2,730 individuals treated as of YE 2024 and a 69% share of treated amenable patients, indicating strong market penetration within its specific patient population.
• Pombiliti + Opfolda's 4-year data from the PROPEL OLE study showing stability or improvement in muscle function, strength, and biomarkers provides a strong long-term efficacy profile, which is crucial for rare disease therapies.
• Real-world evidence presented by independent researchers comparing cipaglucosidase alfa + miglustat (Pombiliti + Opfolda) to alglucosidase alfa and avalglucosidase alfa suggests Pombiliti + Opfolda may offer significant increases in 6MWD (6-minute walk distance) and decreases in 10MWT (10-meter walk test time), outperforming or showing better trends than avalglucosidase alfa in these key functional measures for Pompe disease.
• The DMX-200 program for FSGS, a rare and fatal kidney disease with no approved therapies, positions Amicus to potentially introduce a first-in-class treatment, addressing a critical unmet medical need. The FDA and Project PARASOL alignment on proteinuria as a primary endpoint for approval aligns with standard regulatory pathways for kidney disease therapies.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, achievement of GAAP profitability, increased cash position, and reiterated positive financial guidance, potentially leading to increased share value.
• Patients: Continued access to Galafold and Pombiliti + Opfolda in more countries, and progress in the DMX-200 study for FSGS, offering hope for new treatment options for rare diseases.
• Employees: Positive outlook due to company growth and expansion, potentially leading to job stability and opportunities.
• Suppliers/Partners: Continued demand for manufacturing and services, as evidenced by EMA approval for WuXi Biologics' manufacturing site.

Next Steps

• Complete full enrollment for the Phase 3 ACTION3 study of DMX-200 by end of 2025.
• Continue commercial expansion of Pombiliti + Opfolda in up to 10 new launch countries in 2025.
• Host a conference call and webcast on November 4, 2025, to discuss Q3 results.
• File Quarterly Report on Form 10-Q.
• Anticipate an interim analysis for ACTION3 Part 2 after a planned follow-up meeting with the FDA.
• Await final analysis (2-year proteinuria and eGFR data) for ACTION3 Part 3 for full approval of DMX-200.

Key Dates

Recommendation

The company has demonstrated exceptional operational execution, achieving GAAP profitability ahead of schedule and delivering robust double-digit revenue growth across its commercial portfolio. The strong cash position, positive full-year guidance, and significant progress in the DMX-200 Phase 3 trial for a high-unmet-need indication (FSGS) underscore a compelling growth trajectory. The reiterated target of over $1 billion in sales by 2028, coupled with a leverageable rare disease infrastructure, positions Amicus Therapeutics as a strong investment opportunity with sustainable long-term value creation potential.

Keywords

Amicus Therapeutics, FOLD, Fabry disease, Pompe disease, FSGS, Galafold, Pombiliti, Opfolda, DMX-200, rare diseases, biotechnology, financial results, Q3 2025, revenue growth, GAAP net income, commercialization, clinical trials, rare kidney disease, enzyme replacement therapy